Kepler Capital analyst Albin Sandberg maintained a Buy rating on Castellum (ONOV – Research Report) on October 11 and set a price target of SEK170.00. The company’s shares closed yesterday at $0.14.
According to TipRanks, Sandberg is an analyst with an average return of -11.3% and a 35.45% success rate.
The analyst consensus on Castellum is currently a Moderate Buy rating.
See today’s best-performing stocks on TipRanks >>
Based on Castellum’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $328.61 thousand. In comparison, last year the company had a GAAP net loss of $252.16 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castellum, Inc. is a biotech company, which engages in the development of water treatment and sanitization technologies. It focuses on acquiring and growing technology companies in the area of information technology. The company offers solutions to food, water and health industries. The company was founded by Jean Machetel Ekobo in September 2010 and is headquartered in Phoenix, AZ.
Read More on ONOV:
